<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347125</url>
  </required_header>
  <id_info>
    <org_study_id>CLD 0201</org_study_id>
    <nct_id>NCT01347125</nct_id>
  </id_info>
  <brief_title>ImCardia for DHF to Treat Diastolic Heart Failure (DHF) Patient a Pilot Study</brief_title>
  <acronym>ImCardia</acronym>
  <official_title>ImCardia for DHF - Safety and Functionality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CorAssist Cadiovascular Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CorAssist Cadiovascular Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the ImCardia safety and to demonstrate system&#xD;
      functionality in patients undergoing AV replacement with respect to 36 months follow up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    CorAssist believes that certain improvements are needed to the device&#xD;
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Adverse event reporting</measure>
    <time_frame>36 month</time_frame>
    <description>Adverse event reporting will continue up to 36 month follow up. Any complication attributed to the device will be recorded.&#xD;
Any Major Adverse Cardiac Event (MACE) will be evaluated in a safety committee composed from company representative and a cardiosurgeon which is not part of the company</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functionality - Successful Device implantation</measure>
    <time_frame>Immediately post implantation day</time_frame>
    <description>The surgeon will score device implantation procedure post operation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Heart Failure With Normal Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>ImCardia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aortic Stenosis patients candidates for Aortic Valve Replacement (AVR) implanted with the ImCardia device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVR control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Aortic stenosis patients candidates for aortic valve replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ImCardia Device</intervention_name>
    <description>The device operates by harnessing energy expended by the left ventricle (LV) during Systole and returning it to the heart during Diastole thereby making it available to augment diastolic performance</description>
    <arm_group_label>ImCardia</arm_group_label>
    <other_name>IMC 01</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female able to understand and sign a informed consent&#xD;
&#xD;
          2. Be 50 years of age or older&#xD;
&#xD;
          3. NYHA class III, IV&#xD;
&#xD;
          4. EF &gt;55%&#xD;
&#xD;
          5. Candidates for aortic valve replacement due to aortic stenosis.&#xD;
&#xD;
          6. Agrees to attend all follow- up evaluations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Free wall thickness less than11.5mm&#xD;
&#xD;
          2. Adhesions are expected from a previous surgery or medical condition (e.g. s/p chest&#xD;
             radiation therapy etc.)&#xD;
&#xD;
          3. Presence of significant myocardial scars (e.g. postinfarction) at proposed site for&#xD;
             implant of ImCardia™device Attachment screw.&#xD;
&#xD;
          4. Likely to be need CABG following the implantation of the ImCardia™&#xD;
&#xD;
          5. Intra-cardiac thrombus/mass&#xD;
&#xD;
          6. Myocarditis&#xD;
&#xD;
          7. Acute/chronic pericarditis&#xD;
&#xD;
          8. Not a candidate for sternotomy&#xD;
&#xD;
          9. Active infection&#xD;
&#xD;
         10. Stroke, surgery or ICD within 3 months&#xD;
&#xD;
         11. Acute coronary syndrome during the past 6 months&#xD;
&#xD;
         12. Left ventricular regional wall motion abnormalities&#xD;
&#xD;
         13. Significant valvular disease other that aortic stenosis&#xD;
&#xD;
         14. Significant pulmonary disease&#xD;
&#xD;
         15. A history of alcohol abuse, drug addiction, or other psychosocial condition that would&#xD;
             preclude successful participation, or clear judgment and informed consent in the&#xD;
             opinion of the Principal Investigator&#xD;
&#xD;
         16. Participating in another trial (other than non-therapeutic or interventional&#xD;
             observation) within the last 60 days.&#xD;
&#xD;
         17. History of noncompliance to medical therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lea Lak, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>CorAssist Cardiovascular</affiliation>
  </overall_official>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>April 28, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <last_update_submitted>May 3, 2011</last_update_submitted>
  <last_update_submitted_qc>May 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Lea Lak</name_title>
    <organization>CorAssist Cardiovascular Ltd.</organization>
  </responsible_party>
  <keyword>DHF (diastolic heart failure)</keyword>
  <keyword>HFNEF (heart failure with normal ejection fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

